Significant Accounting Policies (Tables)

3 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Impact of New Revenue Standard on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard on our opening balance sheet:

	Balance at September 30, 2018			New Revenue Standard Adjustment			Balance at October 1, 2018
PROPERTY, PLAN AND EQUIPMENT
Machinery, equipment and furniture	$	50,606		$	8,696		$	59,302
Accumulated depreciation and amortization		(55,846	)		(7,611	)		(63,457	)
OTHER ASSETS
Deferred instrument costs, net		1,239			(1,239	)		—
NON-CURRENT LIABILITIES
Deferred income taxes		(3,769	)		38			(3,731	)
SHAREHOLDERS’ EQUITY
Retained earnings		(49,602	)		116			(49,486	)

Summary of Disaggregation of Revenue

The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics only):

Revenue by Reportable Segment & Geographic Region

	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Americas	$	31,147	$	31,575		(1	)%
EMEA		5,085		5,415		(6	)%
ROW		433		500		(13	)%
Total Diagnostics		36,665		37,490		(2	)%
Life Science-
Americas		4,534		5,250		(14	)%
EMEA		7,455		5,185		44	%
ROW		2,826		4,358		(35	)%
Total Life Science		14,815		14,793		—	%
Consolidated	$	51,480	$	52,283		(2	)%

Revenue by Product Platform/Type

	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Molecular assays	$	7,298	$	8,717		(16	)%
Immunoassays & blood chemistry assays		29,367		28,773		2	%
Total Diagnostics	$	36,665	$	37,490		(2	)%
Life Science-
Molecular reagents	$	6,589	$	5,688		16	%
Immunological reagents		8,226		9,105		(10	)%
Total Life Science	$	14,815	$	14,793		—	%

Revenue by Disease State (Diagnostics only)

	Three Months Ended December 31,
	2018		2017		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	18,633	$	20,270		(8	)%
Respiratory illness assays		7,977		7,486		7	%
Blood chemistry assays		4,466		4,266		5	%
Other		5,589		5,468		2	%
Total Diagnostics	$	36,665	$	37,490		(2	)%